Premium
EBEACOPP WITH OR WITHOUT RITUXIMAB IN INTERIM‐PET‐POSITIVE ADVANCED‐STAGE HODGKIN LYMPHOMA: UPDATED RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 GHSG HD18 TRIAL
Author(s) -
Borchmann P.,
Goergen H.,
Kobe C.,
Eichenauer D.,
Greil R.,
Lohri A.,
Novak U.,
Markova J.,
Beck H.,
Meissner J.,
Zijlstra J.M.,
Ostermann H.,
FeuringBuske M.,
Dierlamm J.,
Eich H.,
Baues C.,
Rosenwald A.,
Fuchs M.,
Diehl V.,
Kuhnert G.,
Dietlein M.,
Engert A.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_52
Subject(s) - medicine , procarbazine , rituximab , etoposide , vincristine , leukocytopenia , prednisone , abvd , progression free survival , chemotherapy , lymphoma , cyclophosphamide , nuclear medicine , oncology , gastroenterology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom